Menu

Category: Pharma Industry

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3

Tom Mirga, Editor at Large Views
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 3 of 6—The Path From Thalidomide, to Revlimid, to a 340B Whistleblower Lawsuit

The myeloma drugs Revlimid and Pomalyst are analogues of Thalomid, aka thalidomide—a drug that still haunts those who remember the late 1950s and early 1960s. Marketed

…
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 2

Tom Mirga, Editor at Large Views
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 2 of 6—A Pharmaceutical Industry Insider’s Claims of Massive Fraud Against 340B Providers

Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or

…
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 1

Tom Mirga, Editor at Large Views
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 1 of 6—Why Can So Few 340B Hospitals Buy and Dispense the Highly Profitable Cancer Drug Revlimid?

Possibly more than a thousand hospitals in the 340B drug discount program can’t buy or dispense Revlimid, a widely-used oral drug

…
Read More »

Two Drug Makers Providing Refunds for 340B Overcharges

Tom Mirga, Editor at Large Views
Drug manufacturers Xellia and Chartwell have notified 340B covered entities about possible refunds for overcharges. | Shutterstock

Drug manufacturers Xellia Pharmaceuticals and Chartwell Rx have notified 340B covered entities about possible refunds for overcharges.

Xellia Pharmaceuticals

Xellia notified 340B covered entities about refunds for overcharges on 16 NDCs for its antibiotics vancomycin, daptomycin, and colistimethate.

Xellia posted

…
Read More »

Much Cheaper PrEP Drugs Could Mean Financial Upheaval for 340B Covered Entities

Ron Shinkman Views
Broad availability of low-cost generic pre-exposure prophylaxis drugs could significantly reduce 340B covered entities' revenues on billings for PrEP. | Shutterstock

Correction, Tuesday, May 25, 4:50 p.m. ET – Earlier today, we reported that the wholesale acquisition price for some of the generic PrEP products is now less than $30 per pill. The correct price is less than $30 per

…
Read More »

United Therapeutics Delays its 340B Claims Data Upload Requirement

Tom Mirga, Editor at Large Views
United Therapeutics pushed back a contract pharmacy claims data sharing requirement for 340B covered entities from today to Sept. 1.

United Therapeutics is holding off on requiring 340B covered entities to turn over their contract pharmacy claims data in order to get 340B pricing on drugs shipped to those pharmacies. The policy was supposed to take effect today. It will

…
Read More »

Takeda Pharmacy Partner Forcing 340B Pricing Opt-in/Opt-out Choice on Entities

Tom Mirga, Editor at Large Views
Takeda business partner Foundation Care is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing “on eligible product purchases,” as a condition for obtaining a Takeda leukemia drug | Shutterstock

Drug manufacturer Takeda’s designated specialty pharmacy and distributor for its leukemia drug Iclusig is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing on purchases, as a condition for obtaining

…
Read More »

Bristol-Myers Squibb Hires Apexus VP Richardson to Be its 340B Strategist

Tom Mirga, Editor at Large Views
Long time Apexus vice president Katheryne Richardson is Bristol-Myers Squibb's new 340B strategist.

Katheryne Richardson, a long time Apexus vice president who was instrumental in launching its 340B University educational program and Apexus Answers call center, is moving to Bristol-Myers Squibb (BMS) to become the drug manufacturer’s 340B program strategist.

Her move to

…
Read More »

State Attorney General Is Investigating Lilly and AstraZeneca’s 340B Pricing

Tom Mirga, Editor at Large Views
Eli Lilly and AstraZeneca are the latest drug makers to disclose that they have been subpoenaed by Vermont's top law enforcement official for documents and information about their participation in 340B. | Shutterstock

Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.

Lilly and …

Read More »

Nonprofit Generic Drugmaker Civica Is Providing Refunds for 340B Overcharges

Tom Mirga, Editor at Large Views
Nonprofit generic drug manufacturer Civica said it has updated its 340B pricing as it obtains baseline average manufacturer price (AMP) data from generic drug manufacturers that make the same products. | Marco Verch https://www.flickr.com/photos/30478819@N08/

Civica, the nonprofit generic drug manufacturer that health systems created in response to drug shortages, owes 340B covered entities refunds for overcharges on 13 NDCs from April 13, 2020 through Feb. 23, 2021.

Civica posted a public notice this

…
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live